ModerateSSRI (selective serotonin reuptake inhibitor)×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Citalopram is a selective serotonin reuptake inhibitor (SSRI). Drugs that interfere with serotonin reuptake, citalopram included, increase the risk of bleeding, and anticoagulants may add to this risk (US citalopram prescribing information, US Food and Drug Administration, FDA). For this reason the citalopram SmPC recommends caution in patients who take anticoagulants at the same time (citalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The edoxaban SmPC warns that, as with other anticoagulants, SSRIs may raise the risk of bleeding through their reported effect on platelets (edoxaban SmPC, EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).
Symptoms
The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Changes in skin bleeding time, bruising, and gynaecological, gastrointestinal and other skin or mucosal bleeding have been described with selective serotonin reuptake inhibitors (SSRIs), citalopram included (citalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Such bleeding has ranged from bruising, haematoma, nosebleeds and petechiae to life-threatening haemorrhage (US citalopram prescribing information, US Food and Drug Administration, FDA).
Management
The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Use citalopram with caution in patients who take anticoagulants and in patients with a history of bleeding disorders (citalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Warn the patient about the increased risk of bleeding (US citalopram prescribing information, US Food and Drug Administration, FDA). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Citalopram, Seropram 30 mg (nº registro 63564) (2024)– AEMPS, CIMA, nº registro 63564 (Seropram 30 mg comprimidos recubiertos con película, Lundbeck), revisión 01/2024, secciones 4.2, 4.3, 4.4, 4.5 y 5.1
- FDA: Celexa (citalopram) – Prescribing Information (2023)– FDA, DailyMed SPL, Allergan, setid 4259d9b1-de34-43a4-85a8-41dd214e9177, version 40, revised 10/2023, sections 4, 5.2, 5.3, 5.4, 7, 12.3 and 17
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2